Gladman D D
Wellesley Hospital, Toronto, Ontario, Canada.
Curr Opin Rheumatol. 1995 Sep;7(5):402-8. doi: 10.1097/00002281-199509000-00007.
This article summarizes the evidence for improved prognosis in patients with systemic lupus erythematosus (SLE), including reasons for improved survival, as well as the risk for mortality, which remains high for patients with this disease. Causes of death are reviewed, and prognostic factors are examined. Other outcome measures for prognosis in SLE, including specific organ damage, accumulated damage index, health status, and quality of life are considered. The continuing controversy regarding the use of cyclophosphamide is reviewed, together with new therapeutic approaches.
本文总结了系统性红斑狼疮（SLE）患者预后改善的证据，包括生存改善的原因以及该疾病患者仍然很高的死亡风险。回顾了死亡原因并检查了预后因素。还考虑了SLE预后的其他结局指标，包括特定器官损害、累积损害指数、健康状况和生活质量。回顾了关于环磷酰胺使用的持续争议以及新的治疗方法。
